Quick Comparison Table

$1,000-$1,200/mo (brand) $1,300-$1,400/mo (brand) $1,000-$1,200/mo (brand) Contact provider for current pricing Contact provider for current pricing Contact provider for current pricing

Zepbound vs. Wegovy (Semaglutide 2.4 mg)

This is the comparison most patients ask about. Both are weekly injectables, both produce transformative weight loss, and both are FDA-approved specifically for chronic weight management.

Head-to-Head Data: SURMOUNT-5

The SURMOUNT-5 trial directly compared tirzepatide (up to 15 mg) against semaglutide (2.4 mg) in 751 adults with obesity over 72 weeks. Results:

• Tirzepatide: 20.2% average weight loss
• Semaglutide: 13.7% average weight loss
• Difference: Tirzepatide produced 47% more weight loss than semaglutide

Tolerability

Surprisingly, Zepbound had lower GI side effect rates than Wegovy despite producing more weight loss. Nausea affected 24% of Zepbound patients vs. 44% on Wegovy. Discontinuation due to side effects was 4.3% vs. 6.8%. The GIP component of tirzepatide may have a protective effect against GLP-1-related nausea.

Cardiovascular Data

Wegovy currently has more robust cardiovascular outcomes data. The SELECT trial (17,604 patients) demonstrated a 20% reduction in MACE. The SURPASS-CVOT trial for tirzepatide also showed cardiovascular benefit, but SELECT was larger and published first. Both medications are considered cardiovascular-protective.

Cost and Access

Wegovy lists at approximately $1,349/month vs. Zepbound at $1,059/month. Through manufacturer programs, Zepbound may be available at $399 to $549/month via LillyDirect, while Wegovy has its own savings programs. Insurance coverage varies: some plans cover one but not the other. Contact provider for current pricing

Bottom Line

Zepbound produces more weight loss with fewer side effects. Wegovy has a longer track record and more cardiovascular outcomes data. If both are equally accessible and affordable, Zepbound is the stronger choice for most patients. If only Wegovy is covered by your insurance, it remains an excellent option. Zepbound vs Wegovy detailed comparison

Zepbound vs. Mounjaro

This is the simplest comparison: Zepbound and Mounjaro contain the exact same active ingredient (tirzepatide) at the same doses. The difference is purely regulatory and insurance-related.

• Mounjaro: FDA-approved for type 2 diabetes
• Zepbound: FDA-approved for chronic weight management

If you have type 2 diabetes, your provider will prescribe Mounjaro. If your primary goal is weight management without diabetes, Zepbound is the appropriate prescription. Some providers have prescribed Mounjaro off-label for weight loss in patients without diabetes, particularly when insurance covers Mounjaro but not Zepbound. This is a legitimate clinical decision, but coverage rules are becoming stricter.

Zepbound vs. Ozempic (Semaglutide 0.5 mg to 2 mg)

Ozempic is FDA-approved for type 2 diabetes, not weight loss. It contains semaglutide at lower doses than Wegovy (max 2 mg vs. Wegovy's 2.4 mg). Many patients have used it off-label for weight loss.

Key Differences

• Weight loss: Ozempic at 1 mg produces approximately 10 to 14% weight loss in diabetes patients vs. Zepbound's 20.9% in the weight management population.
• Mechanism: Ozempic activates only GLP-1 receptors; Zepbound activates both GIP and GLP-1.
• Indication: Ozempic is for diabetes; Zepbound is for weight management. Using Ozempic for weight loss is off-label.
• Insurance: Ozempic is more widely covered by insurance (for diabetes) than Zepbound (for weight loss).

If you have type 2 diabetes and weight loss is a secondary goal, Mounjaro (tirzepatide for diabetes) would be the appropriate comparison to Ozempic. If weight loss is your primary goal and you do not have diabetes, Zepbound is far more effective than off-label Ozempic. Ozempic for weight loss

Zepbound vs. Contrave (Naltrexone/Bupropion)

Contrave is an oral medication that combines an opioid antagonist (naltrexone) with an antidepressant (bupropion). It works through entirely different pathways than Zepbound.

Efficacy

Contrave produces average weight loss of 5 to 8% over 56 weeks, roughly one-third to one-quarter of what Zepbound achieves. In the COR-I trial, patients on Contrave lost an average of 6.1% of body weight vs. 1.3% on placebo.

Advantages of Contrave

• Oral tablet (no injections)
• Much lower cost ($80 to $120/month with GoodRx)
• May help with cravings related to food addiction pathways (opioid receptor blockade)
• Bupropion component can improve mood and is FDA-approved for depression and smoking cessation

Disadvantages Compared to Zepbound

• Significantly less weight loss
• No cardiovascular outcomes data
• Carries a boxed warning for suicidal thoughts (bupropion component)
• Cannot be used with opioid medications
• Side effects include nausea, headache, constipation, and insomnia

Who Might Choose Contrave

Patients who cannot afford Zepbound, have needle phobia, or have a history of food-related addictive behaviors may benefit from Contrave. It is also a reasonable option for patients who need modest weight loss (15 to 20 pounds) rather than the larger reductions Zepbound targets. Contrave for weight loss

Zepbound vs. Qsymia (Phentermine/Topiramate)

Qsymia combines a stimulant appetite suppressant (phentermine) with an anticonvulsant (topiramate) that independently reduces appetite.

Efficacy

The EQUIP trial showed Qsymia at the top dose (15/92 mg) produced 10.9% average weight loss over 56 weeks. The recommended dose (7.5/46 mg) produced 7.8%. These results fall between Contrave and Wegovy.

Advantages of Qsymia

• Oral tablet
• Lower cost ($70 to $100/month with discount cards)
• Better weight loss than Contrave
• Topiramate can help prevent migraines (dual benefit for migraine sufferers)

Disadvantages Compared to Zepbound

• Less than half the weight loss of Zepbound
• Phentermine is a controlled substance (Schedule IV) with abuse potential
• Topiramate can cause cognitive effects ("brain fog"), tingling, taste changes
• Contraindicated in pregnancy (topiramate is teratogenic)
• No cardiovascular benefit data
• Phentermine raises heart rate and blood pressure

Zepbound vs. Phentermine (Generic)

Phentermine alone is the oldest and cheapest prescription weight loss option. It has been available since 1959 and is FDA-approved for short-term use (up to 12 weeks).

Efficacy

Studies show phentermine produces 3 to 5% body weight loss over 12 weeks. Extended use (off-label) may produce 5 to 7% loss. These results are modest compared to Zepbound.

The Case for Phentermine

At $15 to $30 per month, phentermine is the most affordable option by far. For patients who need to lose a small amount of weight and cannot access or afford newer medications, it provides a real (if limited) benefit. Some providers use it as a "bridge" while patients wait for insurance approval of Zepbound or Wegovy.

The Case Against Phentermine

The weight loss is modest, it is only approved for short-term use, it raises heart rate and blood pressure, and weight regain is common after discontinuation. For patients with significant obesity (BMI 35+), phentermine alone is unlikely to produce clinically meaningful improvement.

Zepbound vs. Bariatric Surgery

Until recently, bariatric surgery was the only treatment that produced 20%+ weight loss. Zepbound has narrowed that gap significantly.

Contact provider for current pricing

When Surgery May Still Be Better

For patients with BMI above 40 (or 35+ with severe comorbidities) who need more than 25% weight loss, bariatric surgery may produce superior results. Surgery also has the advantage of being a one-time procedure rather than ongoing treatment. Some patients use Zepbound first and transition to surgery if results are insufficient.

When Zepbound May Be Better

For patients with BMI 27 to 40, those who want to avoid surgery, those who do not qualify for or want surgery, or those who prefer a reversible approach, Zepbound offers transformative results without the risks of a surgical procedure.

Combining Zepbound With Surgery

A growing trend in obesity medicine is using Zepbound before or after bariatric surgery. Pre-surgical use can help patients lose 10 to 15% of body weight before the procedure, reducing surgical risk and potentially improving outcomes. Post-surgical use can help patients who experience weight regain years after their procedure. These are off-label applications that should be managed by experienced providers.

Zepbound vs. Oral GLP-1 Medications

A newer category of competitors deserves mention: oral GLP-1 receptor agonists. Oral semaglutide (Rybelsus, approved for diabetes) has been available for several years, and higher-dose oral semaglutide formulations for weight loss are in late-stage development.

Oral Semaglutide (Rybelsus)

Currently available at doses up to 14 mg daily for type 2 diabetes. Weight loss is approximately 6 to 8% at this dose, significantly less than injectable tirzepatide. The advantage is that it is a daily pill rather than a weekly injection. However, Rybelsus has strict dosing requirements: it must be taken on an empty stomach with no more than 4 ounces of water, and you cannot eat or take other medications for at least 30 minutes afterward.

Future Oral Options

Higher-dose oral semaglutide (25 mg and 50 mg) is being studied for weight loss in the OASIS trial program. Early results suggest weight loss of 15 to 17% at the highest dose. Oral tirzepatide is also in development. These could eventually provide pill-based alternatives to injectable Zepbound, though they are not yet FDA-approved for this purpose.

Bottom Line

For now, injectable Zepbound remains the most effective option. Oral GLP-1 medications for weight loss are on the horizon but not yet competitive with Zepbound's 20.9% results. Patients who strongly prefer pills over injections should discuss currently available oral options with their provider while keeping an eye on upcoming approvals.

How to Choose the Right Option

Here is a decision framework based on the most common patient scenarios:

If Maximum Weight Loss Is Your Priority

Zepbound is the first choice among medications. If Zepbound is not accessible, Wegovy is the next best option. If neither injectable is feasible, Qsymia produces the most weight loss among oral options.

If Cost Is Your Primary Constraint

Generic phentermine ($15 to $30/month) is the cheapest. Contrave and Qsymia ($70 to $120/month with discount cards) offer better results at moderate cost. Zepbound through LillyDirect ($399 to $549/month) is the most cost-effective option among injectables.

If You Cannot Use Injections

Oral options include Contrave, Qsymia, and phentermine. An oral form of semaglutide (Rybelsus) is also available, though it is approved for diabetes rather than weight loss and produces less weight loss than the injectable form.

If You Have Type 2 Diabetes

Mounjaro (tirzepatide for diabetes) or Ozempic (semaglutide for diabetes) are the appropriate choices, as they address blood sugar control alongside weight loss and are more likely to be covered by insurance.

If You Have Cardiovascular Disease

Zepbound or Wegovy, both of which have demonstrated cardiovascular risk reduction in major outcomes trials. cardiovascular benefits of GLP-1 medications

If You Have Tried Other Medications Without Success

Patients who did not respond well to older oral medications (phentermine, Contrave, Qsymia) frequently achieve excellent results on Zepbound. The dual GIP/GLP-1 mechanism works through fundamentally different pathways than older weight loss drugs, so a lack of response to one does not predict failure with the other. Similarly, patients who found semaglutide (Wegovy/Ozempic) partially effective may see additional benefit from switching to tirzepatide's dual-agonist approach.

If You Are Considering Bariatric Surgery

Zepbound can serve as either an alternative to or a bridge toward bariatric surgery. For patients with a BMI of 35 to 45, Zepbound may produce sufficient weight loss to avoid surgery entirely. For patients with a BMI over 50, Zepbound can help reduce surgical risk by lowering weight before the procedure. Some bariatric surgeons now recommend a 3 to 6 month course of GLP-1 medication before surgery to improve outcomes and reduce operative complications. Discuss this option with both your prescriber and your surgical team.

If You Are Young (18-30)

Younger patients tend to respond well to all weight loss medications due to faster metabolism and greater metabolic flexibility. However, long-term data on tirzepatide use in young adults spanning decades does not yet exist. For younger patients, the emphasis on building sustainable lifestyle habits alongside medication is particularly important, as these habits will need to carry you through a potentially very long treatment timeline.

If You Are Over 65

Older patients may benefit from a more conservative approach. The risk of muscle loss (sarcopenia) during weight loss is higher in older adults, making protein intake and resistance training even more critical. Zepbound or Wegovy at moderate doses, paired with aggressive muscle preservation strategies, is generally preferred over higher-risk options like phentermine (which raises blood pressure and heart rate) or surgery. Zepbound side effects

Combination Approaches

Some patients and providers explore combining multiple weight loss strategies for enhanced results. Here is what the evidence supports.

Zepbound Plus Lifestyle Intervention

The SURMOUNT-3 trial studied this exact approach. Patients first underwent a 12-week intensive lifestyle intervention (structured diet and exercise), then added tirzepatide. The combined approach produced total weight loss exceeding 25% of body weight in many participants, suggesting that structured lifestyle changes amplify the medication's effects. This is the most well-supported combination approach.

Zepbound Plus Metformin

Metformin is sometimes added to GLP-1 therapy for patients with insulin resistance or prediabetes. The combination is well-tolerated and may provide a modest additional weight loss benefit (1 to 3% beyond Zepbound alone). However, both medications can cause GI side effects, so the combination may increase nausea and diarrhea in the early weeks.

Zepbound Plus Contrave

Some providers prescribe Contrave (naltrexone/bupropion) alongside GLP-1 medications for patients who struggle with emotional eating or food addiction patterns that the GLP-1 does not fully address. Contrave works on different brain pathways (opioid and dopamine systems) and may complement GLP-1 therapy for select patients. This combination is off-label and should only be used under close provider supervision.

Sequential Therapy

Some patients start with a less expensive medication (phentermine, Contrave, or compounded semaglutide) and then transition to Zepbound if initial results are insufficient. This approach can demonstrate insurance companies that cheaper options were tried first (potentially satisfying step therapy requirements) while still getting patients to the most effective treatment.

How to Switch Between Medications

If you are currently on another weight loss medication and considering switching to Zepbound, here is what to know about the transition.

From Wegovy to Zepbound

No washout period is needed. Your provider will choose a Zepbound starting dose based on your current semaglutide dose. Typical conversions: patients on Wegovy 2.4 mg may start Zepbound at 5 mg or 7.5 mg rather than the standard 2.5 mg initiation dose, since your body is already adapted to GLP-1 receptor activation. GI side effects are usually milder than starting from scratch.

From Ozempic to Zepbound

Similar to Wegovy, no washout period is required. Patients on Ozempic 1 mg or 2 mg are typically started at Zepbound 5 mg. The transition often produces additional weight loss since Zepbound's dual mechanism provides benefits beyond what semaglutide alone offers.

From Oral Medications to Zepbound

Patients switching from Contrave, Qsymia, or phentermine to Zepbound can generally start at the standard 2.5 mg initiation dose since these medications work through different mechanisms that do not prepare the body for GLP-1/GIP receptor activation. Oral medications are typically discontinued at the time of the first Zepbound injection.

From Zepbound to Another Medication

If you need to switch away from Zepbound (due to cost, side effects, or personal preference), the transition should be managed carefully to minimize weight regain. Your provider may start the new medication before fully stopping Zepbound, creating an overlap period to maintain appetite suppression. Weight monitoring should be more frequent during transitions. telehealth weight loss consultation

Frequently Asked Questions

Can I switch from Wegovy to Zepbound?

Yes. Your provider can transition you from semaglutide to tirzepatide. There is no required washout period. Your provider will determine the appropriate starting dose of Zepbound based on your current Wegovy dose and response.

Is Zepbound better than Wegovy for everyone?

Not necessarily. While Zepbound produces more weight loss on average, some individuals respond better to semaglutide. If Wegovy is producing excellent results for you, there may be no reason to switch. The "best" medication is the one that works well for you and that you can access consistently.

Can I combine Zepbound with other weight loss medications?

This is an area of active clinical interest. Some providers combine Zepbound with metformin (for insulin-resistant patients) or with topiramate (for additional appetite suppression). However, Zepbound should not be combined with other GLP-1 receptor agonists (like Wegovy or Saxenda). Always discuss combinations with your provider.

What about new medications in the pipeline?

Several next-generation obesity medications are in clinical development, including triple agonists (GIP/GLP-1/glucagon), oral GLP-1 agonists, and amylin-based therapies. Eli Lilly's own retatrutide (a triple agonist) showed 24.2% weight loss in Phase 2 trials. These are not yet available but may provide additional options in the coming years.

Should I try a cheaper option first before Zepbound?

Some insurance plans require "step therapy" (trying cheaper medications first). If your plan does not require this, there is no medical reason to start with a less effective medication. Starting with the most effective option gives you the best chance of meaningful, sustained weight loss.

Find the Right Medication for You

Comparing weight loss medications is complex, and the best choice depends on your specific health profile, insurance, budget, and goals. Our providers at Form Blends evaluate all of these factors to recommend the option that gives you the best chance of success. Schedule a consultation to discuss your options.

Book Your Free Consultation